• Cybin announces appointment of established pharma industry figure as new CEO
• Drysdale leverages 30 years of leadership, entrepreneurial experience in life-science space
• Announcement comes as Cybin sets out on path to profitability

Cybin Corp., an innovative life science company developing mushroom-derived psychedelic pharmaceuticals and nonpsychedelic nutraceutical products, has announced the appointment of Mr. Doug Drysdale as the company’s Chief Executive Officer. With more than three decades of experience, the new leader recognizes psychedelics as a major breakthrough in treating mental health conditions. Drysdale joins Cybin to pave the road for the company’s rapid growth, underpinned by the recent strong push for research and commercialization in the psychedelics sector.

“With his myriad business accomplishments, Doug is the ideal leader for Cybin,” said Cybin co-founder and Chief Operating Officer Paul Glavine. “We believe that his extensive health-care sector background and international company management skills will help Cybin strengthen partnerships, develop strategic alliances and expand our international presence. We believe his strong leadership experience will help focus Cybin during its initial path to profitability.”

With more than 30 years of successful entrepreneurial experience, Drysdale has led hundreds of business development transactions and executed 15 M&A deals in the international environment life-science sector. Drysdale’s unique skill set reflects both his executive and entrepreneurial experience honed as he led the turnaround of Norwich Pharmaceuticals, becoming the founding CEO of parent company Alvogen. In that role, he helped the company grow from inception to $450 million in five years with revenues generated across 35 countries and a product development pipeline of over 50 products for the U.S. market.

As a well-known figure in the pharma space, Drysdale was recognized by “Pharmaceutical Executive” magazine as a 2011 Emerging Leader and received the 2012 Ernst & Young Entrepreneur of the Year Award. He was also named the 2011 International Business Award Distinguished Honoree for Executive of the Year (Pharmaceuticals).

Drysdale holds a bachelor’s degree in microbial and molecular biology from the University of East Anglia in the United Kingdom. He brings to his new position a wealth of knowledge and experiences in the health-care sector. Previously, he served as director and CEO of Tedor Pharma, a contract manufacturing business featured in the 2020 Inc. 5000 list as one of the fastest-growing companies in the country. Prior to Tedor Pharma, Drysdale was chairman and CEO of Pernix Therapeutics, a life-science company that he helped grow from $80 million to an estimated $800 million, raising $465 million of capital.

Drysdale is quick to spot opportunities as they emerge. “I am beyond excited to be joining the Cybin team,” said Drysdale. “I believe Cybin’s business model and talented management team uniquely position the company to examine the efficacy of psychedelic-based therapies and delivery systems in treating mental illness and addiction disorders. I expect Cybin’s expanding development pipeline will allow Cybin to additionally explore a cost-effective and timely array of health-care alternatives. We will continue to organically grow our IP portfolio and shall be looking to add to our IP through accretive acquisitions.”

As a pioneer in pharmaceutical psychedelics, Cybin is poised to engineer the development of psilocybin-based medicine designed to potentially alleviate major depressive disorders. In the process, opening up a new path to rapid growth and sustainable profitability, seems inevitable.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://nnw.fm/Cybin

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Last Friday, the Vermont House gave an early approval to a proposal that would issue automatic expungements of cannabis convictions, thus allowing people to possess and also grow more marijuana without the risk of getting jailed for a longer time than is allowed.

In the bill, people who have been convicted for cannabis possession for amounts up to 2 ounces, 4 fully grown marijuana plants and 8 immature plants before January 2021 will have their records cleared automatically, and the individuals who are granted expungements will be notified through the mail.

Despite the state legalizing possession of up to an ounce of marijuana and the growing of 2 plants in 2018, possessing a second ounce of marijuana or 3 plants is still considered a felony. If the new bill is passed, this would change.

The legislation also states that from 2021, individuals who have basic marijuana possession convictions will be allowed to deny that record in license, civil rights or employment. This is regardless of whether they have obtained a notice of their expungement being processed or not.

This provision was included by the House Judiciary Committee, which acquired jurisdiction over this legislation after Senate approved the bill earlier in May this year.

Individuals who are caught in possession of the decriminalized amounts mentioned above may face a fine of up to $100 for a first misdemeanor, $200 for a second misdemeanor and $500 for any subsequent offenses.

Matt Simon, who is the political director of the Marijuana Policy Project, New England stated in a recent interview that Vermont had a chance to move forward in terms of cannabis policy and establish an equitable market if S.54 and S.234 were made into laws.

Furthermore, the Senate and the House both approved bills to create a tax-regulated model for cannabis sales. Up until now however, the bills have not been enacted and activists as well as legislators in the state are still calling for the legalization of cannabis sales.

In a draft platform for 2020, Democratic Party insiders from Vermont included plans to legalize cannabis sales and decriminalize drug possession. The document is still subject to change though, based on the comments from delegates and county committees at the party’s meeting Saturday.

Vermont is not the only state pushing for expungement of records. In Virginia, both chambers of the state legislature approved proposals last week that would help individuals expunge prior cannabis convictions from their records.

It is believed that the entire cannabis industry, including The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER), is pleased that Vermont is pressing ahead with marijuana policy reform.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

• Net Element’s reverse merger with EV manufacturer Mullen Technologies expected to close by 4Q2020
• NETE expects to begin marketing Dragonfly K50, sold in conjunction with JV partner Qiantu Motors from 2Q2021
• Company will also break ground in early 2021 on 1.5 million square foot facility to manufacture, assemble its own vehicles
• Zacks forecasts that NETE could snag $30/share valuation by merger’s close

Net Element Inc. (NASDAQ: NETE), a financial technology company which has recently transformed its business model to become a pure-play electric vehicle (“EV”) manufacturer, was recently the subject of a company initiation report published by Zacks Small-Cap Research (https://ibn.fm/XGMRy). Following from Net Element’s decision to enter into a binding Letter of Intent to merge with privately-held Mullen Technologies Inc. in mid-June 2020, the company has sought to divest itself of its legacy payments-as-a-service transactional model and alter its operational focus towards the electric vehicle space. Now, having utilized Net Element’s EV manufacturing peer group’s average valuation of 10x EV/Sales as a comparable, Zacks Small-Cap Research has forecast that Net Element’s share price could be worth $30.00 once the Mullen reverse-merger is fully complete.

The completion of the triangular reverse merger between Net Element and Mullen Technologies is conditional on the combined entity receiving NASDAQ approval along with the completion of a $10 million capital raise, with Zacks anticipating the deal to close by 4Q2020.

During a recent presentation carried out by Mullen Technologies at JP Morgan’s Virtual Auto Conference, the company announced that it would partner with Chinese EV manufacturer, Qiantu Motors to market and sell its vehicles in the United States – with Mullen Technologies having reportedly arrived at an agreement to sell Qiantu’s Dragonfly K50 from 2Q2021 onwards.

Separately, the company also revealed that it had entered into a letter of intent with the City of Spokane to build a 1.5 million sq. ft. facility to manufacture and assemble vehicles, with work on the facility set to commence in early 2021. Remarkably, Mullen Technologies has also revealed that it expects to get to its production phase with as little as $400 million in invested capital over five years (compared to the $1 billion traditionally required) due to its current vehicle IP, which has already been two years in the making.

In addition to its partnership with Qiantu Motors, Mullen Technologies now plans to introduce its self-manufactured EV SUV, the Mullen MX-5 by the second quarter of 2022, with hopes to reach a production threshold of 35,000 vehicles per annum by 2026.

With Net Element’s existing shareholders expected to own between 15% and 21.7% of the post-merger amalgamated entity and utilizing a 10x enterprise value to sales multiple, Zacks Investment Research have estimated that NETE shares could be worth $70 per share by 2023, assuming no further equity dilution. However, by taking a conservative approach which has factored in risk and dilution and time, Zacks’ equity research team believes that the share price could easily surpass the $30 per share mark once the deal closes.

For more information, visit the company’s website at www.NetElement.com.

NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

• In its most recent SEC filings, WTER announced record first-quarter revenue of $14.2 million
• Alkaline88 ranked as 10th best-selling value-added water and third fastest-growing value-added water in Nielsen report
• WTER marks milestone by adding the largest food-service redistributor to its growing list of channel partners

The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER) continues its impressive upward trajectory, releasing record numbers in its latest financial report and ranking in a top-10 category in a recent Nielson report. In addition, with the announcement of its recent distribution agreement with DOT Foods, the company is aggressively expanding into the hospitality channel.

In its most recent SEC filings, WTER announced that it delivered a record first-quarter revenue of $14.2 million (https://cnw.fm/we6Gz), representing a revenue increase of approximately 40% year over year and 18% sequentially. The company also reported fiscal first-quarter earnings per share of ($0.05), which improved 57% compared to the prior-year quarter. In addition, during its most recent earnings call, The Alkaline Water Company indicated that its July’s purchase orders were the second highest of any month.

“Fiscal 2021 is off to a solid start with strong momentum across all our lifestyle brands,” said WTER president and CEO Richard A. Wright. “We delivered record fiscal Q1 revenue of $14.2 million and showed operational discipline with expenses down 5% year-over-year. During the last six months, we have performed exceptionally well, and according to Nielsen data, we outperformed the value-add water category by approximately 12% on a dollar sales basis and 16% on a unit basis. Our operational excellence during the pandemic is creating significant goodwill with existing channel partners, who are showing a stronger commitment to our brands, especially our single-serve, aluminum, and flavored water offerings.”

In addition, the recent “pantry-stuffing” run on basic essential resulted in a significant boon for The Alkaline Water Company. “During the pandemic, Alkaline88(R) was able to meet our retailer’s demands,” said Wright (https://cnw.fm/dys5G). “We believe that up to 30% more households tried our water during our fiscal Q4. This is highlighted by the recent Nielsen report, where Alkaline88(R) was ranked as the 10th best-selling value-added water, and the third fastest-growing, top-ten, value-added water in the country during the 13 weeks ending May 16, 2020.”

Finally, The Alkaline Water Company recently announced a partnership with DOT Food Inc., which will offer the entire line of Alkaline88, A88 Flavor Infused waters, and eco-friendly aluminum bottles to its 4,300 customers nationwide by September 21, 2020 (https://cnw.fm/TcJ5h). “Adding the largest food-service redistributor, Dot Foods, to our growing list of channel partners is another milestone for the company,” said Wright.

“Every year, Dot Foods sells millions of cases of beverages to its customers,” he continued. “This relationship will give us an entry into the hospitality industry, which we view as a significant opportunity for our growing lifestyle brands. There are over 600,000 restaurants and food-service establishments that will now have access to our full line of products. The U.S food-service industry is nearly equal in size to food retailing and accounted for over $969.4 billion in sales in 2019. Our lifestyle brand extension into flavors and aluminum bottles is one of the major reasons Dot Foods viewed Alkaline88 as an important brand to add to its portfolio of products.”

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88, is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils, and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules, and gummies.

To learn more about the company, visit www.A88CBD.com and www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Scientists from UC, San Diego have finally worked out an enigma in human gene activation. As illustrated in the journal Nature, this discovery may be used to control gene activation in biomedical and biotechnology applications.

For a long time, scientists have known that the human genes act using instructions that are delivered by the specific order of a human’s DNA. This is directed by the 4 types of individual links, coded C, A, T and G.

About 25% of a human’s genes are transcribed in sequences resembling TATAAA, which is referred to as the TATA box. However, for the remaining 75%, it’s still a mystery how the genes are turned on or promoted, given the huge number of DNA link sequence possibilities.

Using artificial intelligence, researchers at UC San Diego have discovered a DNA activation code that is used almost as often as the TATA box in human beings. This discovery, which the scientists termed as the DPR (downstream core promoter region), may be used in the future to control gene activation.

A distinguished professor from UC San Diego’s Division of Biological Sciences and the senior author of the paper, James T. Kadonaga, stated that the DPR identification shows an important stage in the activation of roughly 75% of a human’s genes. He also credited the discovery of this new information to the use of machine learning.

About 3 decades ago in 1996, Kadonaga together with his colleagues discovered a gene activation sequence while they were working in fruit flies, which they named the DPE. It enables the turning on of genes in the absence of the TATA box. Since that time though, the research has stalled in terms of deciphering additional details concerning the human DPE.

For this study, Kadonaga collaborated with Cassidy Yunjing Huang, post-doctoral scholar and lead author, Long Vo Ngoc, Claudia Medrano and Jack Cassidy, who is a retired computer scientist that assisted the team in acquiring the necessary tools of artificial intelligence.

The study results showed the existence of the Downstream core Promoter Region motif in human genes. Additionally, the occurrence frequency of the DPR is comparable to the TATA box one. They discovered that the genes that were activated with the TATA box sequences lacked the DPR sequences.

In the future, the use of artificial intelligence to analyze DNA sequence patterns will increase scientists’ ability to study and understand and also control gene activation in human cells. Analysts say this technology could open up new applications for biomed companies like Predictive Oncology (NASDAQ: POAI).

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

The need for clean, sustainable energy could not have been greater. As polar ice caps melt and wildfires become commonplace, governments have put in motion plans to replace carbon based energy with cleaner solar and wind derived energy. Electric cars will play a big part in reducing our carbon emissions, but there are a couple of factors standing in the way of widespread electric vehicle (“EV”) adoption. Chief among them is cost: electric vehicles are crazy expensive to produce and unfortunately, these costs are usually passed down to the consumer, thus confining most EVs on the market to high income individuals.

In Connecticut, the board overlooking the state’s electric vehicle program has been pondering on how to tweak the program to incorporate used vehicles and attract more low-to-moderate-income buyers, something the EV space has been lacking. A proposal that’s under consideration would maintain the current point-of-sale rebates of $1,500 for new electric vehicles with a battery range of more than 200 miles and $500 for all others. Additionally, a supplemental rebate of $1,500 to $2,000 would be available to income-eligible households, a first for the state.

However, many of the 100-plus public comments submitted last month in response to the proposal have said that the base rebate amounts are too low, especially compared to neighboring states. According to comments submitted to the Sierra Club’s Washington, D.C. office, the $1,500 max is well below that of New Jersey, New York and Massachusetts which offer new vehicle rebates from $2,000 to $5,000.

The low rebates were set last October when the Connecticut Hydrogen and Electric Automobile Purchase Program was low on funding. To stretch out the remaining funding to 2020, the Department of Energy and Environmental Protection lowered the rebates. Although the reduced rates led to a reduction in the number of rebates issued, staff at the Department of Energy and Environmental Protection were wary of raising the base rebates as they are adding used vehicle rebates and income-eligible supplements this year, says Paul Farrell, the agency’s Director of Air Planning.

The agency’s new governing board was established by legislation that was passed last year, with the legislation providing for $3 million in annual funding through 2025. According to the agency’s recent Electric Vehicle Roadmap, the new level of funding will support an estimated 13,000 to 16,000 rebates over five years, depending on price trends, availability of federal incentives, and economic conditions.

Experts say companies like Net Element Inc. (NASDAQ: NETE) could be pleased that the state authorities are proactively finding ways to make electric vehicles more affordable for the general public.

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

In recent years, researchers have demonstrated the various health benefits that soy possesses. Some have linked the consumption of soy to reduced cancer, obesity as well as improved bone health. Now researchers from WSU are planning to utilize the benefits of soy to help better postoperative bone cancer treatment.

In the Acta Biomaterialia journal, Naboneeta Sarkar, a graduate student and Susmita Bose, professor from the school of Mechanical and Materials Engineering, WSU, demonstrated that the steady release of chemical compounds that are soy-based from a bone-structure that was 3D printed led to the decrease of osteosarcoma cells as well as harmful inflammation and increasing healthy cells.

Prof. Bose stated that there hadn’t been much research done in this field, especially using natural medicinal substances in biomedical machines. Using natural substances may help better a person’s health with minimal or no side effects. However, the serious issue lies in how to control the composition of these natural medicines.

Despite it being rare, osteosarcoma occurs mostly in young adults as well as children. Patients with metastatic bone cancer and osteosarcoma experience a high recurrence rate, even with the numerous advancements that have been made in the medical field. In children, osteosarcoma comes up as the 2^nd leading cause of cancer-related deaths.

Treatments of these cancers involves having an operation to remove the cancerous tumors then preoperative and post-operative chemotherapy. As areas of the bones affected need to be removed and mended, patients usually experience notable inflammation during reconstruction of the bones. This slows down the healing process. Additionally, the many doses of chemotherapy that are administered before and also after surgery have harmful side effects.

Researchers are therefore trying to develop treatment options that are less harsh, especially post-surgery when the patients are struggling to recuperate from the bone damage while also ingesting strong drugs to help suppress the growth of other tumors. Bose and her team have been studying the engineering of bone tissue to repair bones as a different approach, using advanced manufacturing methods to create effectual biomedical devices.

In this research, the team used 3D printing to form bone structure frames that were patient-specific and comprised of 3 soy compounds. They steadily released the soy compounds into the samples that contained bone cancer and those that had healthy bone cells. Two of the soy compounds improved healthy bone cell growth significantly while the remaining one induced a 90% decrease in the feasibility of the bone cancer cells in their specific samples after an 11-day period.

Bose stated that the results from these findings advanced their understanding in providing therapeutic relief using synthetic bone grafts as a way to deliver the drugs.

The research is still continuing but the work that has been done so far is more than commendable. It’s amazing what knowledge passion and empathy can uncover. Analysts say this commendable work is likely to be welcomed by the biomedical community, including companies like DarioHealth Corp. (NASDAQ: DRIO).

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• Predictive Oncology presenting at upcoming LD 500 investor conference
• Investor event will take place Sept. 1-4, 2020 and will feature 500 handpicked companies from across North American listed micro-cap universe
• Predictive Oncology specializes in applying data and artificial intelligence to cancer personalized medicine, drug discovery

Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has announced that it will be presenting at the upcoming LD 500, an investor conference set to take place in an entirely virtual setting Sept. 1-4, 2020 (http://ibn.fm/42UBB). With 500 handpicked companies in attendance, this year’s conference is set to be among the largest micro-cap focused events globally with thousands of investors expected to attend.

LD Micro, the organizer of the LD 500 conference, was founded in 2006 with the purpose of providing an independent news resource for investors focusing on the microcap space. Initially a newsletter highlighting unique companies, the event has transformed itself into a series of influential conferences held annually– bringing together some of today’s most interesting smaller and micro-cap publicly listed companies and investors focusing on the space.

The LD 500 conference will be the company’s most ambitious event to date, hosting a selection of 500 of North America’s most promising micro-cap companies over a series of four days. The virtual event is set to include a series of keynote addresses and one-on-one meetings, where investors will be able to meet with corporate management teams to receive updates on ongoing corporate operations while posing queries of their own.

“We are delighted to be hosting our virtual event in order to showcase some of the truly unique names in micro-cap,” stated LD Micro president Chris Lahiji. “There are many people and companies who are unable to attend our live events, due to any number of reasons, so we are happy to offer an additional way for companies to present to investors without taking a lot of time out of their day-to-day operations. While virtual events will never replace the experience of sitting in the same room as other humans, it is a great format for updating the investor community and getting increased exposure.”

Predictive Oncology focuses on building AI-driven predictive models of tumor drug response and outcomes from its database of drug-response and genomic profiles gathered from more than 150,000 cancer cases. Through its subsidiary Helomics, POAI is bringing this cutting-edge technology to cancer research, where it’s working with the pharmaceutical, diagnostic and biotech industries to develop predictive models of how tumors response to drugs. These models can be used both for clinical decision support and research into new therapies.

Meanwhile, the company’s wholly-owned TumorGenesis subsidiary specializes in the field of ovarian cancer, creating laboratory-grown cancer cells which can then be used to assist researchers and clinicians in identifying which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ proprietary Oncology Capture Technology Platform, which isolates and helps categorize an individual patient’s heterogeneous tumor sample to enable the development of a patient-specific treatment plan (http://ibn.fm/YWbtr).

For more information about the company, visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Genetic testing and counseling services may help in determining if a person has the BRCA1 and BRCA2 gene mutations. Some people may have an inherited mutation in either one or both of these genes that increases their risk of breast cancer. These mutations can be passed to an individual from either of their parents and can affect both men and women.

If it turns out that you carry these mutations, then below are some of the options that you have that might help inform you on treatment alternatives as well as cancer prevention. The best person to discuss possible options with is a genetic counselor.

For women, a common option is to undergo screening more frequently. This includes getting a breast exam every 6 months from a health care provider and a breast MRI and mammogram every year. Additionally, there are medications that people who carry BRCA mutations can take to decrease the risk of breast cancer developing.

It should be noted that these medications, which are taken for several years, should be used by women who are at least 35 and are done with family planning as they may cause birth defects. It is therefore important that as a patient, you have a discussion with a specialized health care provider concerning the pros and cons of this medication as well as what to expect from using them.

Premenopausal women are usually given Tamoxifen, which is a medication that is said to benefit women who have BRCA2 mutations, as studies have shown. This is not the only drug in the market though, there are others that are usually prescribed to postmenopausal women, if Tamoxifen does not produce the desired results for them.

If you would prefer not to pump your body full of medications, another option would be to have both breasts surgically removed; a double mastectomy. Studies have shown that this reduces the risk of breast cancer developing by 90% – 95%. However, this is an extremely personal choice and it should not be taken lightly.

A comparison of the mortality rate of breast cancer between those who choose a mastectomy and those who choose increased screenings with breast MRIs and mammograms shows no difference.

Ovarian cancer on the other hand, is another story altogether.

As we still do not have a screening tool for ovarian cancer that is reliable, most genetic counsellors recommend that the ovaries and fallopian tubes be removed for women who have a BRCA1 mutation and are aged between 35-40 and aged between 45 and 50 for women who have the BRCA2 mutation.

Despite the varying statistics, studies have shown that this surgery reduces the risk of ovarian and fallopian tube cancer developing by 80% to 95%.

Additionally, men who have the BRCA1 or BRCA2 mutation have an increased risk of getting prostate cancer. Prostate cancer is extremely aggressive and can develop at a younger age. Therefore, it is recommended that increased screening begin between age 40 – 45. The screening should include a PSA (prostate-specific antigen) and a digital rectal exam every year.

It is widely believed that players in the biomedical field, such as DarioHealth Corp. (NASDAQ: DRIO), could be working on availing more options to people with these gene mutations.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• 180 Life Sciences is a clinical-stage biotechnology company that is developing therapies to combat inflammation in patients with chronic inflammation-related illnesses
• The company is being acquired by special purpose acquisition corporation KBL Merger Corp. IV (NASDAQ: KBLM) and will be listed on the Nasdaq Capital Market under ticker symbol ATNF when the deal closes later this year
• Analysts forecast the anti-inflammatory therapeutics market will be worth $191.42 billion by 2027, growing at a CAGR of 3 percent
• 180 Life Sciences is completing phase 2b/3 clinical trials tackling fibrosis and inflammation-causing TNF substance aberrations

The sudden and surprise impact of the COVID-19 pandemic this year has drawn new attention to the bioreactive intricacies of the inflammatory process (http://nnw.fm/WYUfX) as medical scientists work feverishly to develop a clear response to the crisis that has killed some 900,000 people worldwide (as of September 2020) with millions more seriously affected (http://nnw.fm/qob3O). Even before the virus began its sweep, inflammation was receiving critical attention from rheumatologists because of its significance to a wide array of diseases including arthritis, asthma, psoriasis, and many bowel diseases (http://nnw.fm/FH0Hj).

180 Life Sciences is devoting its clinical-stage biotechnology research to producing solutions that will help health professionals battle inflammation when the body’s natural processes go awry. The company’s primary focus is to treat fibrosis and inflammation using anti-TNF therapy, which seeks to suppress the immune system by blocking the activity of TNF, a substance in the body that can cause inflammation and lead to immune-system diseases.

180 Life Sciences’ lead program is in phase 2b/3 clinical trials and expects to deliver its first results next year. Other clinical trials planned by the company are scheduled to begin later this year, and two additional programs are in the preclinical stage.

KBL Merger Corp. IV (NASDAQ: KBLM), a special purpose acquisition corporation (“SPAC”), recently obtained bridge financing to acquire 180 Life Sciences, a process it expects to complete in Q4 2020. Following the merger, the company will be listed on the Nasdaq Capital Market under ticker symbol ATNF, according to a June news release (http://nnw.fm/vn087).

KBLM has filed its amended S4 with the SEC on August 28, 2020 which is pending SEC clearance.

KBLM has valued 180 Life Sciences at $175 million at a time when analysts with Fortune Business Insights anticipate the anti-inflammatory therapeutics market will grow with a 9.3 percent CAGR through 2027 to generate revenues of $191.42 billion (http://nnw.fm/o4umO).

The company’s phase 2b/3 clinical trials are tackling fibrosis and anti-TNF therapies related to early stage Dupuytren’s disease, frozen shoulder, and post-operative cognitive deficit, while preclinical studies are looking at liver fibrosis and nonalcoholic steatohepatitis.

Two other preclinical studies are tackling inflammatory pain and ulcerative colitis in ex-smokers. Developments in the anti-inflammatory therapeutics field aim to deliver medical responses that have less serious side effects than existing conventional treatments, through more effective targeting of specific conditions.

“Our scientific team has unparalleled expertise and a proven track record of developing unique drugs that are on the market and have improved the lives of millions of people and created companies that were later sold for billions of dollars. We have assembled this world-class team to build a unique, global biotechnology company dedicated to developing novel drugs in a cost-effective manner,” KBL Merger Corp. CEO Dr. Marlene Krauss stated in the June news release.

For more information, visit the company’s website at www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to 180 Life Sciences are available in the company’s newsroom at http://nnw.fm/180

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

• Global nutraceutical market valued at $ 382.51 billion; psychedelic drugs market to reach $6.85 billion
• Cybin deploys two-pronged approach covering both psychedelic pharmaceutical and nutraceutical segments
• As psilocybin continues to prove effective in treating mental health conditions, the company is poised to leverage vast addressable market

Cybin Corp., a Canadian early-stage life sciences company appears ideally positioned in two promising markets: nutraceuticals and psychedelic drugs. Both sectors are projected to see impressive growth in the coming years. Cybin looks to benefit from its growing footprint in both spaces.

In 2019, the global nutraceutical market was valued at $382.51 billion. The market is also expected to grow at a compound annual growth rate (“CAGR”) of 8.3% over the next seven years. Consumers continue to embrace functional foods, or foods that offer benefits beyond basic nutrition, for their wellness benefits (http://nnw.fm/ofkid).

At the same time, the psychedelic drugs market is also projected to reach $6.85 billion by 2027. That forecast is based on increased incidences of mental health disorders as well as growing acceptance of psychedelic drugs. The expected proliferation of psychedelics comes from continued research interest from major academic institutions (http://nnw.fm/okHa0).

Cybin is committed to advancing research and development (R&D) through its intellectual property portfolio in the psychedelic, pharmaceutical and nutraceutical spaces. Based on the company’s unique psilocybin extraction methods, delivery mechanisms and new formulations, a variety of indications for mental health will be addressed.

The company’s business model is structured around two wholly owned divisions across the pharmaceutical and nutraceutical sector: Serenity Life Sciences and Nature’s Journey Inc. Serenity Life Sciences is focused on advancing R&D of psilocybin-based pharmaceutical products. Psilocybin, a naturally occurring, non-habit-forming psychedelic compound derived from mushrooms, is experiencing a strong research revival.

Studies show promising results in the treatment of a number of mental health conditions such as anxiety, depression, PTSD, addiction, eating disorders, ADHD and other conditions (http://nnw.fm/clSQE). Cybin views mushroom-derived psychedelic medicines as brain boosters potentially capable of breaking negative thought patterns. Studies indicate that retraining thought processes with low doses of psychedelics help with mental health conditions affecting hundreds of millions of people worldwide.

Cybin’s Nature’s Journey Inc. is focused on nonpsychedelic medical mushroom extracts. Consumer trend forecasts indicate that adaptogenic mushrooms are the next wave of super nutraceuticals. These products are designed to optimize overall health by enhancing mental wellness, immune-boosting detoxification and general well-being.

Cybin offers a robust, diversified business model with compelling growth opportunities in dual, complimentary sectors. Therefore, investors looking for high-potential investments in growing markets should take note of the company’s two-pronged approach to the psychedelic pharmaceutical and nutraceutical mushroom markets.

For more information about this company, please visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://nnw.fm/Cybin

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Over the next decade or so, most developed countries plan to phase out internal combustion-engine vehicles in exchange for electric vehicles (“EVs”). Not only do they run on clean energy, but EV’s have zero emissions, making them perfect for drivers who are keen on reducing their carbon footprint. Rideshare giant Uber Technologies Inc. (NYSE: UBER) recently announced an ambitious plan to have “100 percent” of rides take place in electric vehicles by 2030 in the U.S., Canada, and Europe, and it is using an interesting strategy to achieve it.

Instead of directly paying drivers to trade their fossil-fuel vehicles for EVs, Uber will impose an extra fee on trips completed in an electric vehicle to incentivize drivers to go green. Under the “Uber Green” plan, the rideshare giant will charge a dollar extra to riders who specifically request a hybrid or a fully electric vehicle in 15 cities in the U.S. and Canada. Drivers using hybrid or electric vehicles to pick up passengers will get an extra 50 cents per ride while drivers who specifically use battery-electric vehicles will get an extra dollar for a total of $1.50 extra per ride.

This will make trips in hybrid or electric vehicles slightly more expensive for Uber customers but the company sees this as a necessary cost to help speed the transition to a zero-emissions fleet. Additionally, Uber says it will also spend $800 million of its own money to help “hundreds of thousands of drivers in the U.S., Canada, and Europe transition to battery EVs by 2025.” The company believes that incentivizing rather than punishing drivers is the best way to achieve zero emissions. Aside from getting a little extra cash per passenger for using an EV, drivers won’t be required to drive electric or hybrid vehicles to make money on Uber’s app, even by 2030.

“During the first lockdown, we saw a glimpse of the positive impacts of the record low emissions as a result of less transportation: blue skies replacing smog among city skylines, wildlife returning and pollution levels falling. Clogged roadways transforming into spaces for walking and cycling,” says Uber CEO Dara Khosrowshahi. “But it won’t last. Emission levels are already heading back to pre-COVID highs as recovery from the pandemic continues. And at Uber, we’ve been thinking about what we can do.”

“We want to take this moment as an opportunity to do more, to do better, and to do our part to drive a green recovery in our cities.”

Experts say it is these kinds of initiatives that companies like Net Element (NASDAQ: NETE) can be proud to associate with since they seek to empower working people while safeguarding the environment.

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

The U.S. Department of Agriculture recently awarded a grant to Penn State that will enable its researchers to study the possibility of SARS-CoV-2 infecting and spreading among livestock.

SARS-CoV-2 stands for Severe Acute Respiratory Syndrome Coronavirus 2. It is the strain of coronavirus that causes the novel coronavirus which resulted in the global pandemic.

The grant, through the USDA’s Agricultural and Food Research Initiative, was awarded to a team that is led by Suresh Kuchipudi, a clinical professor of veterinary and biomedical sciences in the College of Agricultural Sciences.

Kuchipudi notes that the coronavirus pandemic is still the most notable public health crisis that has occurred in the modern era and the unprecedented spread of SARS-CoV-2 globally could pose a serious exposure risk to livestock. In the course of the pandemic, scientists state that the new virus has continuously mutated and there now exist many genetic variations of SARS-CoV-2.

Kuchipudi, who is also Penn State’s Animal Diagnostic Laboratory associate director, explained that the first SARS virus infected less than 9,000 people in 2002 and affected pigs the most.

Despite the fact that the virus was contained quickly and did not spread widely, it showed the ability of the SARS viruses to infect agricultural animals. He said that a spillover SARS-CoV-2 into the agricultural sector would be devastating for the U.S. because the livestock sector plays the vital role of providing a reliable and safe food supply, in addition to jobs and other economic benefits.

The research on the vulnerability of livestock to SARS-CoV-2 will determine whether the virus can mutate and spread in agricultural animals. To be on the safe side, these experiments will be done in a level 3 biosafety environment. Additionally, this team of researchers will be using computer models to evaluate the possibility of the virus infecting the livestock.

The research team will create diagnostic tests that will be used to monitor the presence of SARS-CoV-2 antibodies in livestock. Kuchipudi states that their results might help in the betterment of decision-making strategies with regard to safeguarding the agricultural supply chain as well as the well-being of the farming community, the safety of food and the security and health of livestock.

Huck Institutes of the Life Sciences, Penn State is credited by Kuchipudi for assisting in the quick assembly of a team to establish methods and produce preliminary data. This, he said, helped in securing the competitive grant.  Experts say companies like DarioHealth Corp. (NASDAQ: DRIO) are glad that such an outstanding team of researchers will look into the susceptibility of livestock to COVID-19.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.